Table III.
Association of combined p53 and p73 genotypes with risk of HPV16-associated oral cancer
| Risk groupa | HPV16 status | Cases (n = 326) |
Controls (n = 349) |
Adjusted OR (95% CI)b | ||
| No. | % | No. | % | |||
| Low-risk group | − | 81 | 72.3 | 92 | 84.4 | 1.00 |
| + | 31 | 27.7 | 17 | 15.6 | 2.28 (1.15–4.54) | |
| Medium-risk group | − | 109 | 70.8 | 159 | 89.8 | 1.00 |
| + | 45 | 29.2 | 18 | 10.2 | 3.97 (2.14–7.36) | |
| High-risk group | − | 36 | 60.0 | 55 | 87.3 | 1.00 |
| + | 24 | 40.0 | 8 | 12.7 | 5.11 (2.00–13.0) | |
a
Low-risk group: individuals with p53 Arg/Arg and p73 GC/GC genotypes; medium-risk group: individuals with p53 Arg/Arg and p73 AT carriers or p53 Pro carriers and p73 GC/GC and high-risk group: individuals with p53 Pro carriers and p73 AT carriers.
b
HPV positive versus HPV negative in each stratum; ORs were adjusted for age, sex, smoking and drinking status in logistic regression models.